GA
LAB icon

Gagnon Advisors’s Standard BioTools LAB Stock Holding History

Gagnon Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-672,294
Closed -$1.19M – 28
2024
Q2 		$1.19M Hold
672,294
– – 0.91% 25
2024
Q1 		$1.82M Buy
+672,294
New +$1.62M 1.58% 21

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Advisors's LAB Position: Q3 2024 in Review

Gagnon Advisors sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 672,294 shares — an estimated $1.19M sold.

Gagnon Advisors first reported a position in LAB in Q1 2024 and held it in 2 quarters. The position peaked at $1.82M in Q1 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

  • Gagnon Advisors reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
  • Gagnon Advisors sold 672,294 Standard BioTools shares in Q3 2024, an estimated $1.19M.
  • Gagnon Advisors first reported a position in Standard BioTools in Q1 2024 and held it in 2 quarters.
  • Gagnon Advisors's Standard BioTools position peaked at $1.82M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Gagnon Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.